Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of hypophosphataemic vitamin D-resistant rickets with massive doses of 1 alpha-hydroxy-vitamin D3 during childhood.

Literature DB >> 6246841

Treatment of hypophosphataemic vitamin D-resistant rickets with massive doses of 1 alpha-hydroxy-vitamin D3 during childhood.

Y Seino, T Shimotsuji, T Ishii, M Ishida, C Ikehara, K Yamaoka, H Yabuuchi, S Dokoh.

Abstract

Plasma levels of 1,25 dihydroxy-vitamin D (1,25-(OH)2-D) were low in 3 children with hypophosphataemic vitamin D-resistant rickets (HVDRR) during childhood, but increased after very large doses (0.5 to 2 micrograms/kg per day) of 1 alpha-hydroxy-vitamin D (1 alpha-OH-D3). This treatment has two advantages. Firstly, hypercalcaemia is easily controlled by reducing the dose of 1 alpha-OH-D3 because of its short half-life. Secondly, the administration of 1 alpha-OH-D3 to patients with HVDRR can enhance the tubular reabsorption of phosphate, and this seems desirable in treating HVDRR.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1980 PMID： 6246841 PMCID： PMC1626736 DOI： 10.1136/adc.55.1.49

Source DB: PubMed Journal: Arch Dis Child ISSN： 0003-9888 Impact factor: 3.791

8 in total

1. A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors: J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal: Arch Biochem Biophys Date: 1976-09 Impact factor: 4.013

2. Metabolism of 1alpha-hydroxyvitamin D3 to 1alpha, 25-dihydroxyvitamin D3 in perfused rat liver.

Authors: M Fukushima; Y Suzuki; Y Toira; I Matsunaga; K Ochi; H Nagano
Journal: Biochem Biophys Res Commun Date: 1975-09-16 Impact factor: 3.575

3. Total thyroidal content of iodine in thyrotoxic patients measured by in vivo neutron activation analysis.

Authors: I Robertson; K Boddy; M J Hooper; R D Stevenson; T McGhie; W D Alexander; G M Wilson
Journal: Clin Endocrinol (Oxf) Date: 1976-03 Impact factor: 3.478

4. 1,25-dihydroxyvitamin D3 and 1, alpha-hydroxyvitamin D3 in children: biologic and therapeutic effects in nutritional rickets and different types of vitamin D resistance.

Authors: S Balsan; M Garabedian; R Sorgniard; M F Holick; H F Deluca
Journal: Pediatr Res Date: 1975-07 Impact factor: 3.756

5. Growth and renal control of plasma phosphate.

Authors: J Corvilain; M Abramow
Journal: J Clin Endocrinol Metab Date: 1972-03 Impact factor: 5.958

6. The plasma levels of 25-hydroxyvitamin D in patients with various liver diseases and the response of 25-hydroxyvitamin D to vitamin D treatment.

Authors: Y Seino; T Shimotsuji; H Kai; C Ikehara; H Yabuuchi
Journal: Acta Paediatr Scand Date: 1978-01

7. Competitive protein binding assay for 1,25-dihydroxy-vitamin D in human plasma.

Authors: S Dokoh; R Morita; M Fukunaga; I Yamamoto; K Torizuka
Journal: Endocrinol Jpn Date: 1978-10

8. Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.

Authors: J A Kanis; R G Russell
Journal: Br Med J Date: 1977-01-08

8 in total

6 in total

6. Secondary hyperparathyroidism with 1,25-dihydroxyvitamin D deficiency and pseudohypoparathyroidism in childhood: relationship between plasma 1,25-dihydroxyvitamin D and parathyroid hormone levels and urinary cyclic AMP response to exogenous PTH.

Authors: Y Seino; M Ishida; K Yamaoka; T Shimotsuji; T Ishii; H Yabuuchi; M Fukase; T Fujita
Journal: Eur J Pediatr Date: 1981-02 Impact factor: 3.183

6 in total

Treatment of hypophosphataemic vitamin D-resistant rickets with massive doses of 1 alpha-hydroxy-vitamin D3 during childhood.

1. A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

2. Metabolism of 1alpha-hydroxyvitamin D3 to 1alpha, 25-dihydroxyvitamin D3 in perfused rat liver.

3. Total thyroidal content of iodine in thyrotoxic patients measured by in vivo neutron activation analysis.

4. 1,25-dihydroxyvitamin D3 and 1, alpha-hydroxyvitamin D3 in children: biologic and therapeutic effects in nutritional rickets and different types of vitamin D resistance.

5. Growth and renal control of plasma phosphate.

6. The plasma levels of 25-hydroxyvitamin D in patients with various liver diseases and the response of 25-hydroxyvitamin D to vitamin D treatment.

7. Competitive protein binding assay for 1,25-dihydroxy-vitamin D in human plasma.

8. Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.

1. Treatment of hypophosphataemic vitamin D-resistant rickets.

2. Hypophosphataemic vitamin-D resistant rickets may need phosphate supplements.

3. Early biochemical findings in familial hypophosphataemic, hyperphosphaturic rickets and response to treatment.

4. Activity of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase in a case of X-linked hypophosphataemic rickets.

5. Plasma 1,25-dihydroxyvitamin D concentrations in cords, newborns, infants, and children.

6. Secondary hyperparathyroidism with 1,25-dihydroxyvitamin D deficiency and pseudohypoparathyroidism in childhood: relationship between plasma 1,25-dihydroxyvitamin D and parathyroid hormone levels and urinary cyclic AMP response to exogenous PTH.